The two enantiomers of HA-966 have differing pharmacological activity. The glycine/N-methyl-D-aspartate receptor antagonist activity is specific to the (R)-(+)-enantiomer, whereas the sedative andataxic effects are specific to the (S)-(-)-enantiomer.[5]
(R)-(+)-HA-966 did not induce drug-appropriate responding in animals trained to discriminatephencyclidine (PCP) from saline, suggesting that the glycine receptor ligand (R)-(+)-HA-966 has a significantly different behavioral profile than drugs affecting the ion channel of the NMDA receptor complex.[6]
^Vartanian MG, Taylor CP (Nov 1991). "Different stereoselectivity of the enantiomers of HA-966 (3-amino-1-hydroxy-2-pyrrolidinone) for neuroprotective and anticonvulsant actions in vivo".Neuroscience Letters.133 (1):109–12.doi:10.1016/0304-3940(91)90069-6.PMID1838797.S2CID36483282.
^Dunn RW, Flanagan DM, Martin LL, Kerman LL, Woods AT, Camacho F, Wilmot CA, Cornfeldt ML, Effland RC, Wood PL, et al. (Apr 1992). "Stereoselective R-(+) enantiomer of HA-966 displays anxiolytic effects in rodents".European Journal of Pharmacology.214 (2–3):207–14.doi:10.1016/0014-2999(92)90120-S.PMID1355434.
^Näsström J, Karlsson U, Post C (Feb 1992). "Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice".European Journal of Pharmacology.212 (1):21–9.doi:10.1016/0014-2999(92)90067-E.PMID1313371.
^Singh L, Menzies R, Tricklebank MD (Sep 1990). "The discriminative stimulus properties of (+)-HA-966, an antagonist at the glycine/N-methyl-D-aspartate receptor".European Journal of Pharmacology.186 (1):129–32.doi:10.1016/0014-2999(90)94069-A.PMID2149338.
